To carry out industrial production should be the best way out and choice for in-hospital preparation.
With the development of China's pharmaceutical industry, out of the hospital, industrialized production, should be the best way out and choice of in-hospital preparations, is also the best way to solve its survival dilemma. However, the reality is that a large number of in-hospital preparations are still confined within the hospital.
At present, many inexpensive and effective hospital-made special drugs are facing or have faced discontinuation of production. In response to this phenomenon, the newspaper's special observer, Lito Management Consultants Limited pharmaceutical enterprise management consultant Yang Tao analysis, in-hospital preparations, hospital-made special drugs and inexpensive and effective, the association between the three must have a scientific basis, why is the in-hospital preparations? Why is there no industrial industrial production? Why must in-hospital preparations be sold in their own hospitals? It is because in-hospital preparations have not undergone rigorous pharmacological, toxicological, and rigorous clinical trials. In order to control the risk to a limited extent, in-hospital preparations cannot be approved as official drugs and sold nationwide or even globally.
The industry believes that there are still two problems that need to be solved in order to bring in-hospital preparations to the market: firstly, the review of in-hospital preparations, which is difficult to adapt to the modern new drug development review system, should take efficacy and safety as the core point and establish a new clinically oriented evaluation method to build a new drug development model suitable for Chinese drug preparations; secondly, the intellectual property issue, there is a pull of interests of patent rights between prescribers, hospitals and enterprises, and there is a lack of basic regulation.
Epoxy market changes
2026-09-20
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Egyptian Pharmaceutical Market Research
-
CPHI China 2023 | At the Heart of Pharma
-
A Guide Into What the Pharmaceutical Use of Hexamine Is
-
In line with the 8201, Hengrui Pharmaceutical plans the HER2 ADC in this way
-
$50 billion in products were 'returned' to rationalize those blockbuster BD deals
-
Tronsound long-acting IL-36R antibody obtained FDA clinical IND
-
Dapagliflozin is approved in the EU for the treatment of symptomatic chronic heart failure
-
The FDA accepted Zuranolone's NDA application and granted it priority review rights for the treatment of MDD and PDD
-
Asia Hong Pharma announced that it has co-developed an innovative tumor therapy based on AI+RNA technology route with ReviR
-
Ribo Biologics announced that the world's first FIH application for a siRNA drug targeting FXI has been successfully approved by HREC in Australia
Recommend Reading
-
New Ocean Freight GRI Takes Effect on Asia, Middle East and Africa Routes to U.S. and Canada
-
Sika in China Under Pressure: The Structural Alarm Behind the 1,500-Job Cut
-
IEA Warns Oil Inventories Are Draining Fast as Chemicals Enter Risk Pricing
-
Is India’s “Luck” Finally Here? HPCL’s 10-Year LNG Deal Is a High-Stakes Bet on National Destiny
-
One Million Tonnes of U.S. Ethane Arrive as China Sets a New Import Record
-
Sodium Metabisulfite Prices Rise This Week (Jan. 19–23)
-
Soda ash prices in China rose first and then fell in October
-
Weak Demand Sends Acrylonitrile Market into Sharp Decline
-
cost support dichloromethane center of gravity shifts upward
-
Isopropyl Alcohol Market Prices Rise This Week (Jan. 19–23)